Show simple item record

dc.contributor.authorHoang, D-T
dc.contributor.authorDinstag, G
dc.contributor.authorShulman, ED
dc.contributor.authorHermida, LC
dc.contributor.authorBen-Zvi, DS
dc.contributor.authorElis, E
dc.contributor.authorCaley, K
dc.contributor.authorSammut, S-J
dc.contributor.authorSinha, S
dc.contributor.authorSinha, N
dc.contributor.authorDampier, CH
dc.contributor.authorStossel, C
dc.contributor.authorPatil, T
dc.contributor.authorRajan, A
dc.contributor.authorLassoued, W
dc.contributor.authorStrauss, J
dc.contributor.authorBailey, S
dc.contributor.authorAllen, C
dc.contributor.authorRedman, J
dc.contributor.authorBeker, T
dc.contributor.authorJiang, P
dc.contributor.authorGolan, T
dc.contributor.authorWilkinson, S
dc.contributor.authorSowalsky, AG
dc.contributor.authorPine, SR
dc.contributor.authorCaldas, C
dc.contributor.authorGulley, JL
dc.contributor.authorAldape, K
dc.contributor.authorAharonov, R
dc.contributor.authorStone, EA
dc.contributor.authorRuppin, E
dc.coverage.spatialEngland
dc.date.accessioned2024-07-23T10:43:34Z
dc.date.available2024-07-23T10:43:34Z
dc.date.issued2024-07-03
dc.identifier10.1038/s43018-024-00793-2
dc.identifier.citationNature Cancer, 2024,en_US
dc.identifier.issn2662-1347
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/6313
dc.identifier.eissn2662-1347
dc.identifier.eissn2662-1347
dc.identifier.doi10.1038/s43018-024-00793-2
dc.identifier.doi10.1038/s43018-024-00793-2
dc.description.abstractAdvances in artificial intelligence have paved the way for leveraging hematoxylin and eosin-stained tumor slides for precision oncology. We present ENLIGHT-DeepPT, an indirect two-step approach consisting of (1) DeepPT, a deep-learning framework that predicts genome-wide tumor mRNA expression from slides, and (2) ENLIGHT, which predicts response to targeted and immune therapies from the inferred expression values. We show that DeepPT successfully predicts transcriptomics in all 16 The Cancer Genome Atlas cohorts tested and generalizes well to two independent datasets. ENLIGHT-DeepPT successfully predicts true responders in five independent patient cohorts involving four different treatments spanning six cancer types, with an overall odds ratio of 2.28 and a 39.5% increased response rate among predicted responders versus the baseline rate. Notably, its prediction accuracy, obtained without any training on the treatment data, is comparable to that achieved by directly predicting the response from the images, which requires specific training on the treatment evaluation cohorts.
dc.formatPrint-Electronic
dc.languageeng
dc.language.isoengen_US
dc.publisherNATURE PORTFOLIOen_US
dc.relation.ispartofNature Cancer
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/en_US
dc.subjectScience & Technology
dc.subjectLife Sciences & Biomedicine
dc.subjectOncology
dc.subjectARTIFICIAL-INTELLIGENCE
dc.subjectPROSTATE-CANCER
dc.subjectBIOPSIES
dc.titleA deep-learning framework to predict cancer treatment response from histopathology images through imputed transcriptomics.en_US
dc.typeJournal Article
dcterms.dateAccepted2024-06-06
dc.date.updated2024-07-23T07:36:43Z
rioxxterms.versionAMen_US
rioxxterms.versionofrecord10.1038/s43018-024-00793-2en_US
rioxxterms.licenseref.startdate2024-07-03
rioxxterms.typeJournal Article/Reviewen_US
pubs.author-urlhttps://www.ncbi.nlm.nih.gov/pubmed/38961276
pubs.organisational-groupICR
pubs.publication-statusPublished online
pubs.publisher-urlhttp://dx.doi.org/10.1038/s43018-024-00793-2
icr.researchteamCancer Dynamicsen_US
dc.contributor.icrauthorSammut, Stephen John
icr.provenanceDeposited by Dr Stephen-John Sammut on 2024-07-23. Deposit type is initial. No. of files: 1. Files: s43018-024-00793-2.pdf


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record

http://creativecommons.org/licenses/by/4.0/
Except where otherwise noted, this item's license is described as http://creativecommons.org/licenses/by/4.0/